A new generation of engineered immune cell destroys cancer cells in mice 1 as effectively as conventional CAR-T-cell ...

While interested in CAR-T therapies’ potential to achieve durable, drug-free remission in serious autoimmune conditions, the ...

RNA CAR T therapy Descartes‑08 targets BCMA‑positive plasma cells and delivers year‑long symptom relief in myasthenia gravis ...

A first clinical study suggests allogeneic CD19-targeted CAR-T cell therapy can safely induce durable remission in patients with severe, treatment-refractory systemic lupus erythematosus.

A UCLA research team has identified the best design for a promising new type of immunotherapy that could be mass-produced to ...

Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the launch of ResQ215B, a Phase 2 ...

UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes engineered cancer-fighting immune cells behave more like stem cells, improving ...

Editing CAR T cells to produce inflammatory cytokines helps them enter solid tumors and promote cancer killing.

Mary Bird Perkins Cancer Center has become the first facility in the region to offer a new blood cancer treatment in an ...

An international research team with strong participation from DTU has developed a new biotechnological platform that makes it possible to test and understand advanced cancer treatments much faster and ...

I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...